Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity
US7575750B2 · kind B2 · utility
1Cited by
7References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 23, 2003 |
| Grant date | Aug 18, 2009 |
| Priority date | — |
| Expiry date | Dec 25, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.